Molecular Diagnosis of the Hematologic Cancers
Open Access
- 1 May 2003
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (18) , 1777-1785
- https://doi.org/10.1056/nejmra020067
Abstract
The diagnosis of the hematologic cancers presents a daunting challenge. The many stages of normal hematopoietic differentiation give rise to a number of biologically and clinically distinct cancers. Inherited DNA-sequence variants do not appear to have a prominent causative role; rather, these diverse cancers are typically initiated by acquired alterations to the genome of the cancer cell, such as chromosomal translocations, mutations, and deletions. The diagnosis of the hematologic cancers is commonly based on morphologic evaluation supplemented by analysis of a few molecular markers. However, in some diagnostic categories defined in this fashion, the response of patients to treatment is markedly heterogeneous, arousing the suspicion that there can be several molecularly distinct diseases within the same morphologic category.Keywords
This publication has 37 references indexed in Scilit:
- Inhibition of FLT3 in MLLCancer Cell, 2003
- Role of FLT3 in leukemiaCurrent Opinion in Hematology, 2002
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemiaNature Genetics, 2001
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic LeukemiaThe Journal of Experimental Medicine, 2001
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001
- Genomic Views of the Immune SystemAnnual Review of Immunology, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- TrueLeukemia, 1999
- TrueLeukemia, 1999
- THE CRITICAL ROLE OF CHROMOSOME TRANSLOCATIONS IN HUMAN LEUKEMIASAnnual Review of Genetics, 1998